Helena Wright @Moonwater: "Is $PFE a potential candidate..."

South Africa

Is $PFE (Pfizer) a potential candidate for a portfolio recovery strategy in 2026? Dear Followers and Copiers I am analyzing the fundamentals to see if the current valuation presents an opportunity. While many have focused on Pfizer’s post-COVID revenue reset, the data suggests 2026 is shaping up to be a pivotal year for this biopharma giant. With a 𝟲.𝟰% 𝙙𝙞𝙫𝙞𝙙𝙚𝙣𝙙 𝙮𝙞𝙚𝙡𝙙 —nearly 4x the industry average—Pfizer is paying investors to wait for its next growth cycle. 𝙇𝙞𝙛𝙚 𝘽𝙚𝙮𝙤𝙣𝙙 𝘾𝙊𝙑𝙄𝘿 Pfizer is aggressively diversifying its portfolio. Here are the key catalysts to watch: • 𝘿𝙚𝙧𝙢𝙖𝙩𝙤𝙡𝙤𝙜𝙮: The "Tranquillo" study is testing an oral drug for nonsegmental vitiligo. If successful, this opens a massive new market in dermatology. • 𝙊𝙗𝙚𝙨𝙞𝙩𝙮/𝙈𝙚𝙩𝙖𝙗𝙤𝙡𝙞𝙘: The Phase 1 trial of MET097 (PF-08653944) shows Pfizer is building "optionality" in the high-growth weight-loss space. • 𝙢𝙍𝙉𝘼 𝙁𝙧𝙖𝙣𝙘𝙝𝙞𝙨𝙚: A Phase 2 study for mRNA flu shots is underway, aiming to challenge $MRNA (Moderna Inc) and $SNY (Sanofi-ADR) in the seasonal vaccine market. • 𝙊𝙣𝙘𝙤𝙡𝙤𝙜𝙮 𝙒𝙞𝙣: Positive Phase 3 results for PADCEV + Keytruda in bladder cancer reinforce Pfizer’s dominance in the oncology sector. 𝙏𝙝𝙚 𝘿𝙞𝙫𝙞𝙙𝙚𝙣𝙙 𝙎𝙩𝙧𝙖𝙩𝙚𝙜𝙮 At a 𝟲.𝟰% 𝙮𝙞𝙚𝙡𝙙, Pfizer gets you two-thirds of the way to the historical 10% annual stock market return before the share price even moves. Reinvesting dividends while the stock is "unloved" allows investors to accumulate 𝙨𝙝𝙖𝙧𝙚𝙨 𝙖𝙩 𝙖 𝙙𝙞𝙨𝙘𝙤𝙪𝙣𝙩. The yield is high because of upcoming 𝙥𝙖𝙩𝙚𝙣𝙩 𝙚𝙭𝙥𝙞𝙧𝙖𝙩𝙞𝙤𝙣𝙨. However, Pfizer’s massive scale and M&A history suggest they have the "commercial muscle" to bridge this gap. 𝟮𝟬𝟮𝟲 𝙄𝙣𝙙𝙪𝙨𝙩𝙧𝙮 𝙊𝙪𝙩𝙡𝙤𝙤𝙠 The healthcare sector is forecasted for a strong 2026, driven by: • 𝘼𝙜𝙞𝙣𝙜 𝙋𝙤𝙥𝙪𝙡𝙖𝙩𝙞𝙤𝙣𝙨: Increasing demand for primary and specialty care. • 𝘼𝙄 𝙀𝙛𝙛𝙞𝙘𝙞𝙚𝙣𝙘𝙞𝙚𝙨: AI is accelerating drug discovery and R&D success rates. • 𝘼𝙩𝙩𝙧𝙖𝙘𝙩𝙞𝙫𝙚 𝙑𝙖𝙡𝙪𝙖𝙩𝙞𝙤𝙣𝙨: Healthcare remains undervalued compared to the high-flying tech sector, offering a defensive "value" play. 𝘿𝘾𝙁 Though 2026 is not expected to see a major lift in the stock price unless success materializes earlier than expected, the longer-term growth expectation is supported by the DCF valuations below: 𝙏𝙝𝙚 𝘽𝙤𝙩𝙩𝙤𝙢 𝙇𝙞𝙣𝙚 Pfizer expects 𝟮𝟬 𝙠𝙚𝙮 𝙥𝙞𝙫𝙤𝙩𝙖𝙡 𝙨𝙩𝙪𝙙𝙮 𝙨𝙩𝙖𝙧𝙩𝙨 in 2026. While policy uncertainty and pipeline risks remain, Pfizer’s ability to execute at a global scale remains its defining competitive advantage. Are you holding $PFE for the dividend, or waiting for the pipeline to pop? Let’s discuss below! Best regards Heleen $S&P500 $PFE

Not investment advice. The author may have financial interests in the mentioned instruments.

3 Mentioned

PFE

Pfizer

MRNA

Moderna Inc

SNY

Sanofi-ADR

Strictly Necessary Cookies

Performance Cookies

Functional Cookies

Targeting Cookies